Emerging evidence shows that expression of H19 is upregulated in many cancers, including CRC [13, 14], hepatocellular carcinoma [15, 16], esophageal cancer [17], ovarian cancer [18], breast cancer [19–21] and bladder cancer [22, 23], with or without the loss of imprinting. Here, H19 is linked to cancer.